CLINICAL PERSPECTIVE

This Article Abstract Full Text (PDF) All Versions of this Article: 114/10/1063    most recent CIRCULATIONAHA.105.608869v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Price, J. F. Articles by Dreyer, W. J. Search for Related Content PubMed PubMed Citation Articles by Price, J. F. Articles by Dreyer, W. J. Related Collections Congestive Pediatric and congenital heart disease, including cardiovascular surgery

(Circulation. 2006;114:1063-1069.)
© 2006 American Heart Association, Inc.

Pediatric Cardiology

B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Events in Pediatric Outpatients With Chronic Left Ventricular Systolic Dysfunction

Jack F. Price, MD; Anne K. Thomas, RN, MSN; Michelle Grenier, MD; Benjamin W. Eidem, MD; E. O’Brian Smith, PhD; Susan W. Denfield, MD; Jeffrey A. Towbin, MD; William J. Dreyer, MD

From the Department of Pediatrics, The Lillie Frank Abercrombie Section of Pediatric Cardiology, Baylor College of Medicine, Texas Children’s Hospital, Houston.

Correspondence to Jack F. Price, MD, Texas Children’s Hospital, 6621 Fannin, MC 19345C, Houston, TX 77030. E-mail jprice{at}bcm.tmc.edu

Received December 17, 2005; revision received July 7, 2006; accepted July 10, 2006.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Plasma B-type natriuretic peptide (BNP) levels are elevated in adults with heart failure and correlate with functional classification and prognosis. The range and predictive power of BNP concentrations in children with chronic heart failure, however, are not known.

Methods and Results— Whole blood BNP concentrations were measured in 53 consecutive patients with chronic left ventricular (LV) systolic dysfunction (biventricular hearts, ejection fraction <50%, >3 months since diagnosis). Children who had been hospitalized within 3 months before potential enrollment and those <2 months or >21 years of age were excluded. BNP concentrations were measured with the Triage assay (Biosite Diagnostics, Inc, San Diego, Calif). Echocardiographers and clinicians were blinded to BNP levels. An adverse cardiovascular event was defined as cardiac death, cardiac-related hospitalization, or listing for cardiac transplantation. The median age of patients with LV dysfunction was 9.3 years (interquartile range [IQR], 2.7 to 15.1 years). BNP levels were elevated in children with LV dysfunction compared with healthy controls (median, 78 pg/mL [IQR, 22 to 551 pg/mL] versus median, 7 pg/mL [IQR, 5 to 11 pg/mL]; P<0.0001). Whole blood BNP concentrations were increased in patients who had a 90-day adverse cardiovascular event compared with those who did not (median, 735 pg/mL [IQR, 685 to 1510 pg/mL] versus median, 37 pg/mL [IQR, 14 to 92 pg/mL]; P<0.001). Patients with a BNP concentration 300 pg/mL were at increased risk of death, hospitalization, or listing for cardiac transplantation (adjusted hazard ratio, 63.6; P<0.0001).

Conclusions— BNP concentrations are elevated in children with chronic LV systolic dysfunction and predict the 90-day composite end point of death, hospitalization, or listing for cardiac transplantation.

Key Words: cardiomyopathy • heart failure • natriuretic peptides • pediatrics

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The cardiac hormone B-type natriuretic peptide (BNP) is now widely recognized as a reliable marker of ventricular dysfunction and heart failure in adults. This 32–amino acid peptide is secreted by the ventricular myocardium during situations of increased wall stress caused by excessive volume or pressure loading of the heart.¹ Plasma BNP concentrations are elevated in adults with congestive heart failure and can distinguish cardiac from noncardiac causes of dyspnea, correlate with the severity of heart failure symptoms, and predict mortality and hospital readmission.^2–9 Because of this relationship, plasma BNP concentrations have become a useful tool in both the acute care and outpatient settings to facilitate with the diagnosis, triage, and risk stratification of adult patients with congestive heart failure.^10–13

Clinical Perspective p 1069

Despite the prolific reporting of BNP data in adults with heart failure, very little is known about this hormone in children and even less in children with heart failure. A few small studies have reported normative data for BNP in the pediatric population, but our understanding of the clinical utility of BNP in children with heart failure remains insufficient.^14,15 In fact, no studies have evaluated the role of BNP in pediatric patients with chronic heart failure. Therefore, we sought (1) to determine the range of whole blood BNP concentrations in children with chronic left ventricular (LV) systolic dysfunction and (2) to test the hypothesis that BNP concentrations can predict adverse cardiovascular events.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Study Design
This study was designed as a prospective cohort investigation in which BNP concentrations were measured in consecutive outpatients with chronic LV systolic dysfunction. The Baylor College of Medicine Institutional Review Board approved the study protocol, and procedures were followed in accordance with institutional guidelines, including obtaining written parental consent and, when appropriate, patient assent.

Patient Selection
Subjects were recruited from the outpatient cardiomyopathy and heart failure clinic at the Department of Pediatrics, The Lillie Frank Abercrombie Section of Pediatric Cardiology, Baylor College of Medicine, Texas Children’s Hospital, Houston. The study protocol included symptomatic and asymptomatic patients who had been treated with standard medical therapy for LV systolic dysfunction (ejection fraction [EF] <50%) for at least 3 months. Patients <2 months or >21 years of age were excluded from the study. In addition, patients whose systolic dysfunction was attributable to left-sided obstructive lesions, anyone hospitalized for exacerbation of heart failure symptoms in the preceding 3 months, and patients with a history of structural heart disease or renal failure were also excluded. Healthy children who underwent screening echocardiography in the cardiology outpatient clinic because of an abnormal ECG or heart murmur were enrolled as control subjects. All controls had normal echocardiograms and no evidence of active disease processes.

Echocardiography and Physician Assessment
An echocardiogram was performed on each study patient at the time of enrollment, and LVEF was estimated with the use of the Simpson biplane method. Other echocardiographic measurements obtained included LV end-diastolic dimension (LVEDD), transmitral early diastolic velocity/tissue Doppler early diastolic mitral annular velocity (E/Ea), and myocardial performance index (MPI).¹⁶ The LVEDD was expressed as a deviation from the mean (Z score). Pulsed Doppler was used to determine transmitral blood flow velocity in the apical 4-chamber view. Tissue Doppler velocities were measured at the lateral mitral annulus. A clinical history was taken before BNP testing, and each study subject was examined by a pediatric heart failure specialist.

Primary End Point
The primary end point was the occurrence of an adverse cardiovascular event at 90 days. An adverse cardiovascular event was defined as cardiac death (pump failure or sudden death), hospitalization for cardiac reasons (new onset or worsening of heart failure symptoms), or new listing for cardiac transplantation. When risk of adverse events was determined, patients in whom >1 adverse event occurred were treated as though they had only 1 event.

Measurement of BNP
Plasma BNP levels in study and control subjects were measured in the outpatient clinic with the use of the point-of-care Triage Meter Plus assay (Biosite Diagnostics, Inc, San Diego, Calif). Approximately 250 µL of whole blood was sampled from each subject. The assay can reliably detect BNP concentrations ranging from 5 to 5000 pg/mL and has a coefficient of variation of 9.9% to 12.2%. Both echocardiography staff and clinic physicians were blinded to the BNP values.

Statistical Analysis
Continuous variables are expressed as mean (±SD) or median (interquartile range [IQR]) depending on the distribution of the variable. Groups were compared with the use of either a t test or the Mann-Whitney U test, depending on normality and variance assumptions. The association of categorical variables with high or low BNP concentration was determined by ² analysis. Pearson correlation was used to determine correlation between BNP and echocardiographic variables. Receiver operating characteristic (ROC) curves were generated to determine the accuracy and optimal threshold of BNP and echocardiographic measurements for predicting future adverse cardiovascular events. We compared the areas under the ROC curves using the Hanley-McNeil method.¹⁷ Cox proportional hazards regression was used to determine whether BNP concentrations were predictive of the composite end point over the 90-day time from enrollment. The time to the earliest adverse event was used for creation of a Kaplan-Meier curve. A probability value <0.05 was considered statistically significant.

The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Patient Characteristics
Sixty-three consecutive patients met eligibility criteria, and 53 were enrolled (see Table 1 for patient characteristics). Ten eligible patients were not enrolled because of refusal of a parent to give consent, failure of the investigator to seek enrollment before the patient left the clinic, or unsuccessful phlebotomy. The median age of enrollees was 9.3 years (IQR, 2.7 to 15.1 years), and the median time from diagnosis of LV dysfunction was 22 months (IQR, 5 to 42 months). Fifty-five percent of study subjects had been hospitalized previously for an exacerbation of heart failure symptoms. Eighteen healthy control subjects were also enrolled (median age, 7.9 years; IQR, 3.8 to 13.1 years). The median BNP concentration was 78 pg/mL (IQR, 22 to 551 pg/mL) in study subjects and 7 pg/mL (IQR, 5 to 11 pg/mL) in controls. Whole blood BNP concentrations were significantly greater in study subjects than in control subjects (median, 78 pg/mL [IQR, 22 to 551 pg/mL] versus median, 7 pg/mL [IQR, 5 to 11 pg/mL]; P<0.0001).

View this table: [in this window] [in a new window]   TABLE 1. Clinical Characteristics of LV Dysfunction Patients (n=53)

Echocardiography Data
Median values and ranges of LVEF, LVEDD Z score, LV MPI, and mitral E/Ea are listed in Table 1. Whole blood BNP concentrations correlated with LVEF (r=–0.53, P<0.001) and LV MPI (r=0.45, P<0.002) but did not correlate with LVEDD Z score (r=0.2, P<0.2) or mitral E/Ea (r=0.14, P<0.15). Those patients with at least moderate mitral regurgitation had higher BNP concentrations than patients with less than moderate mitral regurgitation (median, 701 pg/mL [IQR, 192 to 1272 pg/mL] versus median, 48 pg/mL [IQR, 16 to 195 pg/mL]; P<0.003).

Signs and Symptoms
Twenty-one study subjects had at least 1 sign or symptom of heart failure at the time of enrollment. Clinical findings included fatigue or decreased activity level (n=15); dyspnea, orthopnea, or increased work of breathing (n=10); gallop rhythm (n=9); hepatomegaly (n=8); peripheral edema (n=4); syncope or near syncope (n=3); rales (n=2); and diaphoresis (n=1).

Adverse Cardiovascular Outcome
Follow-up data were available for all 53 study subjects. At 90 days after BNP testing, 19 adverse cardiovascular events had occurred in 15 patients. Three patients died from pump failure, 4 patients were listed for cardiac transplantation, and there were 12 hospitalizations for new onset or worsening of heart failure symptoms. Whole blood BNP concentration was significantly greater among patients in whom an adverse event occurred than in patients in whom no adverse event occurred (median, 735 pg/mL [IQR, 685 to 1510 pg/mL] versus median, 37 pg/mL [IQR, 14 to 92 pg/mL]; P<0.001) (Figure 1).

View larger version (21K): [in this window] [in a new window]   Figure 1. BNP concentrations for patients in whom an adverse event occurred vs patients in whom no adverse event occurred (P<0.0001). Whisker lines represent highest and lowest values; shaded area, interquartile values; and middle line, median.

LV Dysfunction With "Normal" BNP Concentrations
Seventeen patients with LV dysfunction had "normal" BNP concentrations (ie, <30 pg/mL). Compared with subjects with BNP concentrations 30 pg/mL, they had a higher LVEF (40±8% versus 33±11%; P<0.02), lower LVEDD Z score (2.0±1.5 versus 3.5±2.1; P<0.02), lower LV MPI (0.50±0.13 versus 0.62±0.16; P<0.03), and lower mitral E/Ea (6.0±2.3 versus 10.0±5.9; P<0.002). They were also less likely to have signs or symptoms of heart failure (3/17 versus 18/36; P<0.04), and none of them suffered an adverse cardiovascular event.

Prognostic Accuracy
To determine the accuracy of a whole blood BNP concentration for predicting an adverse cardiovascular event, a ROC curve was generated. The area under the curve was 0.98 (95% confidence interval [CI], 0.96 to 1.0; P<0.0001), indicating a high degree of prognostic accuracy. A cutoff BNP concentration of 282 pg/mL was found to be the optimal value for discriminating patients at risk for future adverse cardiovascular events. ROC curves were also plotted for LVEF, LVEDD Z score, LV MPI, and mitral E/Ea. The area under the ROC curve for BNP was significantly greater than the area under the ROC curves for LVEF (0.75; P<0.001), LVEDD Z score (0.65; P<0.001), LV MPI (0.8, P<0.03), and mitral E/Ea (0.62, P<0.001). Optimal cutoff values for each echocardiographic feature included an LVEF of 35%, an LVEDD Z score of 2.6, an LV MPI of 0.64, and a mitral E/Ea of 6.9. The sensitivity, specificity, and predictive values for each cutoff value, including a BNP concentration of 300 pg/mL and the presence or absence of heart failure signs or symptoms, are listed in Table 2. A BNP concentration cutoff of 300 pg/mL had the highest sensitivity, specificity, and predictive values (sensitivity, 0.93; 95% CI, 0.66 to 0.99; specificity, 0.95; 95% CI, 0.81 to 0.99; positive predictive value, 0.88; 95% CI, 0.6 to 0.98; negative predictive value, 0.97; 95% CI, 0.84 to 0.99). Both the LV MPI and the presence of heart failure signs or symptoms had weak positive predictive values but strong negative predictive values, whereas LVEF, LVEDD Z score, and mitral E/Ea all had relatively weak predictive values.

View this table: [in this window] [in a new window]   TABLE 2. Sensitivity, Specificity, and Predictive Values of Clinical Evaluations

BNP <300 pg/mL Versus BNP 300 pg/mL
After adjustment for age and gender, subjects with a BNP concentration 300 pg/mL were found to be at increased risk of having an adverse cardiovascular event within 90 days of testing (adjusted hazard ratio=63.6; P<0.0001). They also had a lower LVEF (28±11% versus 38±9%; P<0.003) and greater LV MPI (0.7±0.1 versus 0.5±0.1; P<0.001) than subjects with a BNP concentration <300 pg/mL. Although there was a trend toward an increased LVEDD Z score among subjects with a BNP concentration 300 pg/mL, the difference in means was not statistically significant (3.9±2.8 versus 2.7±1.6; P<0.2). Similarly, there was no difference in E/Ea between the groups (10.9±5.6 versus 8.1±5.4; P<0.2). Patients with BNP levels 300 pg/mL were also more likely to have signs or symptoms of heart failure (13/16 versus 9/37; P<0.001). Nine of 14 patients (64%) with at least moderate mitral regurgitation had a BNP concentration 300 pg/mL. Eight (89%) of those patients subsequently suffered an adverse cardiovascular event. Only 1 patient of 37 with a BNP concentration <300 pg/mL met the primary end point, whereas 14 of 16 patients in the group with a BNP 300 pg/mL remained at risk at 90 days. A Kaplan-Meier curve demonstrates the cumulative freedom from adverse cardiovascular events over time for patients with a BNP <300 pg/mL and patients with a BNP 300 pg/mL (Figure 2). This difference was highly significant (P<0.001).

View larger version (17K): [in this window] [in a new window]   Figure 2. Kaplan-Meier plot of cumulative freedom from adverse cardiovascular events for patients with BNP concentrations <300 or 300 pg/mL, demonstrating a greater incidence of adverse events for the latter group (P<0.001). Among patients with a BNP <300 pg/mL, 36 of 37 remained at risk of the primary end point at 90 days compared with 2 of 16 in the group with a BNP concentration 300 pg/mL.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
These data demonstrate that whole blood BNP concentrations are increased in children with chronic LV systolic dysfunction compared with healthy children. Additionally, BNP concentrations were found to range widely in this population. In fact, some children with LV dysfunction have BNP levels within a range that previously has been described as normal (ie, <30 pg/mL).¹⁵ Moreover, BNP concentrations predicted the 90-day composite end point of death, hospitalization, or listing for cardiac transplantation. A BNP concentration of 300 pg/mL, in particular, appeared to be a strong discriminator of patient morbidity and mortality.

Previous reports have suggested that BNP concentrations are elevated in children with ventricular dysfunction.^18–22 Studies in children, however, have been limited by the relatively small number of eligible subjects or restriction to a cohort with a particular comorbidity (eg, Duchenne muscular dystrophy) or confounded by the inclusion of patients with various types of structural heart disease and cardiac physiologies. With respect to anatomy, physiology, and medical therapy, the cohort in the present study was relatively homogeneous in that all subjects had biventricular hearts with depressed LV systolic dysfunction, and the vast majority were treated with an angiotensin-converting enzyme inhibitor and/or a ß-blocker.

Elevated BNP and LV Dysfunction
Our findings of elevated BNP concentrations in children with chronic LV dysfunction are consistent with neurohormonal data reported in adults.²³ Tsutamoto and colleagues²⁴ found that BNP concentrations were wide ranging in adults with chronic heart failure and that most adult patients (NYHA class II to III) had levels <250 pg/mL. Similarly, our observation that a significant portion of the present cohort had a BNP concentration considered normal has also been described in adults with LV systolic dysfunction.²⁵ Tang andcolleagues²⁶ reported that up to 21% of adult patients with chronic symptomatic heart failure had BNP concentrations below those considered diagnostic of heart failure (<100 pg/mL). Approximately one third of our cohort had a normal BNP level (<30 pg/mL) and, interestingly, 3 patients with normal BNP levels and LV dysfunction also had signs or symptoms of heart failure. Despite being symptomatic, none of those patients suffered an adverse cardiovascular event within 90 days of assessment.

In the present study, BNP was found to be a strong predictor of cardiac mortality and morbidity in children with chronic LV systolic dysfunction. The 90-day adverse cardiovascular event rate among patients with BNP concentrations 300 pg/mL was 88%. These findings are similar to reports in adults with heart failure in which baseline BNP concentrations and changes in BNP over time predicted both mortality and morbidity.^9,13,27 Among patients with stable but symptomatic heart failure in the Valsartan Heart Failure Trial, the relative risk of mortality or first morbid event was 2.1 for patients with a baseline BNP concentration above the median (97 pg/mL).²⁸

Clinical Correlation
Echocardiographic and symptomatic heart failure data could predict adverse cardiovascular events in this cohort to some degree but not with the accuracy of BNP. The echocardiographic measurement with the most satisfactory predictive power for adverse cardiovascular events was the LV MPI (negative predictive value, 97%), a ratio of ventricular relaxation and contraction times that is influenced by both systolic and diastolic properties. The fact that BNP is released in patients with isolated diastolic dysfunction may explain why the LV MPI correlated better with BNP concentrations than some of the other echocardiographic measures.⁵ The mitral E/Ea is also affected by diastolic filling; however, we found no correlation between it and BNP. The sensitivity, specificity, and predictive powers of the mitral E/Ea were relatively weak for the primary end point. Calculating the ratio of transmitral diastolic velocity to tissue Doppler annular velocity is a method of estimating LV filling pressures and has been shown to predict outcomes in adults hospitalized with congestive heart failure.²⁹ In adults, it is also known to have a diagnostic accuracy for congestive heart failure similar to BNP.³⁰ Although the LVEF correlated indirectly with BNP, the more evenly distributed values about the optimal cutoff point of 35% made it a less reliable predictor of adverse events. Similarly, the predictive power of LVEDD Z score was marginal and did not correlate with BNP concentration.

The absence of signs or symptoms of heart failure by medical history and physical examination could help to rule out a future adverse event. The presence of symptoms, however, could not predict a positive event. The poor correlation with BNP and the comparably weak predictive powers of echocardiographic and clinical data suggest that BNP concentration alone may more reliably predict short-term adverse cardiovascular events in children than other standard outpatient evaluation tools.

The accuracy with which BNP predicted clinical deterioration in this cohort speaks more to the ability of this test to reflect the patients’ degree of clinical compensation than its prediction of impaired ventricular contractility. Of 16 patients with an EF 30% in this study, 4 (25%) had normal BNP concentrations. More accurately, this regulatory hormone is a surrogate marker of circulatory compensation, and there is growing evidence in adults to support this concept. Kazanegra and colleagues³¹ demonstrated that falling BNP concentrations parallel the drop in pulmonary capillary wedge pressure in adult patients treated for decompensated heart failure. Maisel and colleagues³ found that BNP levels in adults with heart failure differed significantly as a function of the severity of heart failure symptoms and correlated with NYHA functional classification. Likewise, Lee and colleagues²³ reported the superiority of BNP compared with LVEF for assessing functional classification during the treatment of chronic heart failure. Furthermore, plasma BNP concentrations have been shown to be associated with exercise capacity in adult patients with chronic heart failure, correlating with the impairment of O₂ at peak exercise and anaerobic threshold.³²

As a marker of circulatory compensation, BNP may have valuable adjunctive clinical utility in infants and small children, among whom signs of heart failure commonly are not recognized until overt decompensation occurs and in whom symptoms may not be adequately articulated. We speculate that a measured BNP concentration may be additive to the current clinical assessment of children with chronic LV dysfunction and may help to distinguish those patients at risk of future adverse cardiovascular events. Another subgroup of patients who might benefit from BNP testing is the cohort with at least moderate mitral regurgitation. Systolic ventricular function frequently belies the severity of disease in these patients, and BNP may aid in identifying those at increased risk. All but 1 patient with at least moderate mitral regurgitation who subsequently suffered an adverse cardiovascular event had a baseline BNP concentration >300 pg/mL. Further studies will be necessary to determine a role for BNP in risk stratification of pediatric patients and whether it can demonstrate a response to medical therapy.

Study Limitations
There are several important limitations to this study. BNP levels are elevated in adults with right ventricular dysfunction and/or LV diastolic dysfunction. Because we did not perform formal evaluations of right ventricular function and LV diastolic function, we cannot exclude their influence on this cohort. Similarly, BNP concentrations may also be elevated in patients with renal insufficiency. We did not measure kidney function in this study, but no patients with a history of renal failure were enrolled. Finally, our conclusions should be tempered by the understanding that the patient sample size was small, and the numbers of adverse cardiovascular events were few. This led to widened CIs for the positive predictive value of BNP and may limit our ability to predict the occurrence of an adverse event occurring on the basis of a BNP level >300 pg/mL. More definitive conclusions about the clinical utility of BNP as a marker of circulatory compensation in children with heart failure will require large, multi-institutional studies.

Summary
Whole blood BNP concentrations are increased and range widely in children with chronic LV systolic dysfunction. A subset of these patients have BNP levels that are within the normal range. More importantly, BNP concentrations can predict the 90-day composite end point of death, hospitalization, or listing for cardiac transplantation in pediatric patients with chronic LV systolic dysfunction. We speculate that BNP levels may be a useful clinical adjunct when monitoring pediatric outpatients with ventricular dysfunction, but large multicenter studies should be performed to determine the utility of BNP as a marker of prognosis and outcome.

	Acknowledgments

 
Sources of Funding

The Biosite Triage assay and reagents were provided by Biosite Diagnositics, Inc at no cost.

Disclosures

None.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995; 96: 1280–1287.[Medline] [Order article via Infotrieve]

2. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS. Utility of B-type natriuretic peptide (BNP) in the diagnosis of HF in an urgent care setting. J Am Coll Cardiol. 2001; 37: 379–385.[Abstract/Free Full Text]

3. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrman HC, McCullough PA, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161–167.[Abstract/Free Full Text]

4. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004; 350: 647–654.[Abstract/Free Full Text]

5. Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani S. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005; 11: 498–503.[CrossRef][Medline] [Order article via Infotrieve]

6. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcomes after hospital discharge in patients with heart failure. Am J Med. 2002; 113: 215–219.[CrossRef][Medline] [Order article via Infotrieve]

7. Cheng VL, Kazanegra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel AS. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001; 37: 386–391.[Abstract/Free Full Text]

8. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004; 43: 635–641.[Abstract/Free Full Text]

9. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002; 105: 2392–2397.[Abstract/Free Full Text]

10. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet. 1994; 343: 440–444.[CrossRef][Medline] [Order article via Infotrieve]

11. Maisel A, Hollander J, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004; 44: 1328–1333.[Abstract/Free Full Text]

12. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001; 38: 1934–1941.[Abstract/Free Full Text]

13. Watanabe J, Shiba N, Shinozaki T, Koseki Y, Karibe A, Komaru T, Miura M, Fukuchi M, Fukahori K, Sakuma M, Kagaya Y, Shirato K. Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail. 2005; 11: 50–55.[CrossRef][Medline] [Order article via Infotrieve]

14. Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, Itoh H, Shirakami G, Matsuo H. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol. 1995; 133: 207–209.[Abstract/Free Full Text]

15. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart. 2003; 89: 875–878.[Abstract/Free Full Text]

16. Eidem BW, Tei C, O’Leary PW, Cetta F, Seward JB. Nongeometric quantitative assessment of right and left ventricular function: myocardial performance index in normal children and patients with Ebstein anomaly. J Am Soc Echocardiogr. 1998; 11: 849–856.[CrossRef][Medline] [Order article via Infotrieve]

17. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148: 839–843.[Abstract/Free Full Text]

18. Ohuchi H, Takasugi H, Ohashi H, Okada Y, Yamada O, Ono Y, Yagihara T, Echigo S. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation. 2003; 108: 2368–2376.[Abstract/Free Full Text]

19. Westerlind A, Wahlander H, Lindstedt G, Lundberg PA, Homgren D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr. 2004; 93: 340–345.[CrossRef][Medline] [Order article via Infotrieve]

20. Koulouri S, Acherman RJ, Wong PC, Chang LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol. 2004; 25: 341–346.[Medline] [Order article via Infotrieve]

21. Mori K, Manabe T, Nii M, Hayabuchi Y, Kuroda Y, Tatara K. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne’s progressive muscular dystrophy. Pediatr Cardiol. 2002; 23: 160–166.[CrossRef][Medline] [Order article via Infotrieve]

22. Law Y, Keller B, Feingold B, Boyle G. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol. 2005; 95: 474–478.[CrossRef][Medline] [Order article via Infotrieve]

23. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, Redfield MM, Burnett JC Jr. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 2002; 8: 149–154.[CrossRef][Medline] [Order article via Infotrieve]

24. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997; 96: 509–516.[Abstract/Free Full Text]

25. McGeoch G, Lainchbury J, Town GI, Toop L, Espiner E, Richards AM. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail. 2002; 4: 479–483.[Abstract/Free Full Text]

26. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, Francis GS. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003; 108: 2964–2966.[Abstract/Free Full Text]

27. Berger R, Strecker K, Huelsmann M, Moser P, Frey B, Bojic A, Stanek B, Pacher R. Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transplant. 2003; 22: 1037–1045.[CrossRef][Medline] [Order article via Infotrieve]

28. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HefFT). Circulation. 2003; 107: 1278–1283.[Abstract/Free Full Text]

29. Dokainish H, Zoghbi WA, Lakkis NM, Ambriz EA, Patel R, Quinones MA, Nagueh SF. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol. 2005; 45: 1223–1226.[Abstract/Free Full Text]

30. Dokainish H, Zoghbi WA, Lakkis NM, Quinones MA, Nagueh SF. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol. 2004; 93: 1130–1135.[CrossRef][Medline] [Order article via Infotrieve]

31. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid test for B-type natriuretic peptide correlates with falling wedge pressure in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001; 7: 21–29.[CrossRef][Medline] [Order article via Infotrieve]

32. Kruger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 2002; 40: 718–722.[Abstract/Free Full Text]

---

 

CLINICAL PERSPECTIVE

In this study we sought to determine the range of whole blood B-type natriuretic peptide (BNP) concentrations in children with chronic left ventricular systolic dysfunction and to test the hypothesis that BNP concentrations can predict adverse cardiovascular events. We found that BNP concentrations vary widely in this population and that frequently patients have levels that fall within a range considered "normal." Despite the fact that some of these patients with chronic heart failure and normal BNP concentrations were symptomatic, none of them suffered an adverse cardiovascular event. BNP concentrations were just as reliable as, if not superior to, common echocardiographic measures of function for predicting death, hospitalization, or listing for transplantation at 90 days. Both the positive and negative predictive powers of BNP were high when a cutoff point of 300 pg/mL was used (88% and 97%, respectively). For the clinician, these findings imply that a simple blood test may serve as a reliable and relatively inexpensive adjunct tool when monitoring children with chronic heart failure in the outpatient setting. BNP concentrations appear to consistently correlate with clinical compensation in this cohort and suggest that patients with concentrations >300 pg/mL may benefit from closer surveillance. This tool may be especially useful for those patients who are too young or hesitant to verbalize their symptoms. Further investigations are needed to understand the clinical utility of serial BNP measurements in children with chronic heart failure.

This article has been cited by other articles:

				S. M. Macicek, C. G. Macias, J. L. Jefferies, J. J. Kim, and J. F. Price Acute Heart Failure Syndromes in the Pediatric Emergency Department Pediatrics, November 1, 2009; 124(5): e898 - e904. [Abstract] [Full Text] [PDF]

				Y. M. Law, A. W. Hoyer, M. D. Reller, and M. Silberbach Accuracy of Plasma B-Type Natriuretic Peptide to Diagnose Significant Cardiovascular Disease in Children: The Better Not Pout Children! Study J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1467 - 1475. [Abstract] [Full Text] [PDF]

				D. T. Hsu and G. D. Pearson Heart Failure in Children: Part II: Diagnosis, Treatment, and Future Directions Circ Heart Fail, September 1, 2009; 2(5): 490 - 498. [Full Text] [PDF]

				A. Bernus, B. D. Wagner, F. Accurso, A. Doran, H. Kaess, and D. D. Ivy Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension Chest, March 1, 2009; 135(3): 745 - 751. [Abstract] [Full Text] [PDF]

				J. Mangat, C. Carter, G. Riley, Y. Foo, and M. Burch The clinical utility of brain natriuretic peptide in paediatric left ventricular failure Eur J Heart Fail, January 1, 2009; 11(1): 48 - 52. [Abstract] [Full Text] [PDF]

				J P Kaski, M T Tome-Esteban, S Mead-Regan, A Pantazis, J Marek, J E Deanfield, W J McKenna, and P M Elliott B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy Heart, October 1, 2008; 94(10): 1307 - 1311. [Abstract] [Full Text] [PDF]

				O. Chikovani, J.-H. Hsu, R. Keller, T. R. Karl, A. Azakie, I. Adatia, P. Oishi, and J. R. Fineman B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1179 - 1187. [Abstract] [Full Text] [PDF]

				J.-H. Hsu, R. L. Keller, O. Chikovani, H. Cheng, S. A. Hollander, T. R. Karl, A. Azakie, I. Adatia, P. Oishi, and J. R. Fineman B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 939 - 945. [Abstract] [Full Text] [PDF]

				M. Fenton and M. Burch Understanding chronic heart failure Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 114/10/1063    most recent CIRCULATIONAHA.105.608869v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Price, J. F. Articles by Dreyer, W. J. Search for Related Content PubMed PubMed Citation Articles by Price, J. F. Articles by Dreyer, W. J. Related Collections Congestive Pediatric and congenital heart disease, including cardiovascular surgery